Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician's choice (TPC) Meeting Abstract
| Authors: | Lorusso, D.; Colombo, N.; Herraez, A. C.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; Shapira-Frommer, R.; Kim, Y. M.; McCormack, M.; Massaad, R.; Nguyen, A. M.; Zhao, Q.; McKenzie, J.; Prabhu, V. S.; Makker, V. |
| Abstract Title: | Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician's choice (TPC) |
| Meeting Title: | ESMO Gynaecological Cancers Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2022 Jun 17-18 |
| Meeting Location: | Valencia, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-06-01 |
| Start Page: | S391 |
| End Page: | S392 |
| Language: | English |
| ACCESSION: | WOS:000814982500021 |
| DOI: | 10.1016/j.annonc.2022.04.038 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 20MO -- Source: Wos |
